Angiogenesis inhibition and choroidal neovascularization suppression by sustained delivery of an integrin antagonist, EMD478761

Investigative Ophthalmology and Visual Science

Volumn 48, Issue 11, 2007, Pages 5184-5190

  Fu, Yingli ^a,b   Ponce, M Lourdes ^a   Thill, Michelle ^a   Yuan, Peng ^c   Nam, Sun Wang ^b   Csaky, Karl G ^a,d  

^a NATIONAL EYE INSTITUTE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d DUKE UNIVERSITY EYE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHAVBETA5 INTEGRIN; BASIC FIBROBLAST GROWTH FACTOR; EMD 478761; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; POLYMER; POLYVINYL ALCOHOL; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; ANGIOGENESIS INHIBITOR; BENZOXAZINE DERIVATIVE; EMD478761; FIBROBLAST GROWTH FACTOR 2; INTEGRIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BROWN NORWAY RAT; CHICK EMBRYO; CHORIOALLANTOIS; COMPARATIVE STUDY; CONTROLLED STUDY; DIODE LASER; DRUG EFFECT; DRUG IMPLANT; EXPERIMENTAL MODEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; RAT; SUBRETINAL NEOVASCULARIZATION; SUSTAINED DRUG RELEASE; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; INJECTION; LOW LEVEL LASER THERAPY; MALE; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; VASCULARIZATION; VITREOUS BODY;

ANGIOGENESIS INHIBITORS; ANIMALS; BENZOXAZINES; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; CHOROIDAL NEOVASCULARIZATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; FIBROBLAST GROWTH FACTOR 2; INJECTIONS; INTEGRIN ALPHAVBETA3; INTEGRINS; LASER THERAPY; MALE; NEOVASCULARIZATION, PATHOLOGIC; RATS; RATS, INBRED BN; RECEPTORS, VITRONECTIN; VITREOUS BODY;

EID: 38449113574     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.07-0469     Document Type: Article

References (43)

1. Ferris FL, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984;102:1640-1642.
2. Eichler W, Yafai Y, Wiedemann P, Fengler D. Antineovascular agents in the treatment of eye diseases. Curr Pharm Des. 2006; 12:2645-2660.
3. Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol. 2003;48:257-293.
4. http://www.blindness.org/publications/newsarticle.asp?x=1&NewsID=279. Accessed August 13, 2007.
5. FDA labeling information. http://www.fda.gov/cder/foi/label/2006/ 125156lbl.pdf. 2006. Accessed August 13, 2007.
6. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419-1431.
7. Narayanan R, Kuppermann BD, Jones C, Kirkpatrick P. Ranibizumab. Nat Rev Drug Discov. 2006;5:815-816.
8. Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: phase III clinical trial results. Ophthalmol Clin North Am. 2006;19:361-372.
9. Kisker O, Becker CM, Prox D, et al. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res. 2001;61:7669-7674.
10. Pearson PA, Hainsworth DP, Ashton P. Clearance and distribution of ciprofloxacin after intravitreal injection. Retina. 1993;13:326-330.
11. Heinemann MH. Staphylococcus epidermidis endophthalmitis complicating intravitreal antiviral therapy of cytomegalovirus retinitis: case report. Arch Ophthalmol. 1989;107:643-644.
12. Thompson JT. Cataract formation and other complications of intravitreal triamcinolone for macular edema. Am J Ophthalmol. 2006;141:629-637.
13. Ruiz-Moreno JM, Montero JA, Bayon A, Rueda J, Vidal M. Retinal toxicity of intravitreal triamcinolone acetonide at high doses in the rabbit. Exp Eye Res. 2007;84:342-348.
14. Hynes RO. Integrins: a family of cell surface receptors. Cell. 1987;48:549-554.
15. Friedlander M, Theesfeld CL, Sugita M, et al. Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. Proc Natl Acad Sci USA. 1996;93:9764-9769.
16. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA. Definition of two angiogenic pathways by distinct alpha v integrins. Science. 1995;270:1500-1502.
17. Brooks PC, Montgomery AM, Rosenfeld M, et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994;79:1157-1164.
18. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 1994;264:569-571.
19. Joki T, Machluf M, Atala A, et al. Continuous release of endostatin from microencapsulated engineered cells for tumor therapy. Nat Biotechnol. 2001;19:35-39.
20. Morishita T, Mii Y, Miyauchi Y, et al. Efficacy of the angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (AGM-1470) on osteosarcoma growth and lung metastasis in rats. Jpn J Clin Oncol. 1995;25:25-31.
21. Ponce ML, Hibino S, Lebioda AM, Mochizuki M, Nomizu M, Kleinman HK. Identification of a potent peptide antagonist to an active laminin-1 sequence that blocks angiogenesis and tumor growth. Cancer Res. 2003;63:5060-5064.
22. Wolfe JD, Csaky KG. Indocyanine green enhanced retinal vessel laser closure in rats: histologic and immunohistochemical observations. Exp Eye Res. 2004;79:631-638.
23. Edelman JL, Castro MR. Quantitative image analysis of laser-induced choroidal neovascularization in rat. Exp Eye Res. 2000;71:523-533.
24. Baker RW, ed. Controlled Release of Biologically Active Agents. New York: John Wiley & Sons; 1987.
25. Ishida K, Yoshimura N, Mandai M, Honda Y. Inhibitory effect of TNP-470 on experimental choroidal neovascularization in a rat model. Invest Ophthalmol Vis Sci. 1999;40:1512-1519.
26. Ciulla TA, Criswell MH, Danis RP, Hill TE. Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. Arch Ophthalmol. 2001;119:399-404.
27. Yasukawa T, Hoffmann S, Eichler W, Friedrichs U, Wang YS, Wiedemann P. Inhibition of experimental choroidal neovascularization in rats by an alpha (v)-integrin antagonist. Curr Eye Res. 2004;28:359-366.
28. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol. 2002;120:338-346.
29. Tolentino MJ, Brucker AJ, Fosnot J, et al. Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal neovascularization. Retina. 2004;24:132-138.
30. Clark RA, Tonnesen MG, Gailit J, Cheresh DA. Transient functional expression of αVβ3 on vascular cells during wound repair. Am J Pathol. 1996;148:1407-1421.
31. Kamizuru H, Kimura H, Yasukawa T, Tabata Y, Honda Y, Ogura Y. Monoclonal antibody-mediated drug targeting to choroidal neovascularization in the rat. Invest Ophthalmol Vis Sci. 2001;42:2664-2672.
32. Umeda N, Kachi S, Akiyama H, et al. Suppression and regression of choroidal neovascularization by systemic administration of an α5β1 integrin antagonist. Mol Pharmacol. 2006;69:1820-1828.
33. Wilkinson-Berka JL, Jones D, Taylor G, et al. SB-267268, a nonpeptidic antagonist of alpha (v) beta3 and alpha (v) beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2006;47:1600-1605.
34. Mousa SA, Mohamed S, Wexler EJ, Kerr JS. Antiangiogenesis and anticancer efficacy of TA138, a novel αvβ3 antagonist. Anticancer Res. 2005;25:197-206.
35. Reinmuth N, Liu W, Ahmad SA, et al. αvβ3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice. Cancer Res. 2003;63:2079-2087.
36. Meerovitch K, Bergeron F, Leblond L, et al. A novel RGD antagonist that targets both αvβ3 and α5β1 induces apoptosis of angiogenic endothelial cells on type I collagen. Vasc Pharmacol. 2003;40:77-89.
37. Kumar CC, Malkowski M, Yin Z, et al. Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha (v) beta3 and alpha(v) beta5 integrin receptor antagonist. Cancer Res. 2001;61:2232-2238.
38. Roberts M, Barry S, Woods A, van der Sluijs P, Norman J. PDGF-regulated rab4-dependent recycling of αvβ3 integrin from early endosomes is necessary for cell adhesion and spreading. Curr Biol. 2001;11:1392-1402.
39. Hughes A. A schematic eye for the rat. Vision Res. 1979;19:569-588.
40. Robinson MR, Baffi J, Yuan P, et al. Safety and pharmacokinetics of intravitreal 2-methoxyestradiol implants in normal rabbit and pharmacodynamics in a rat model of choroidal neovascularization. Exp Eye Res. 2002;74:309-317.
41. Ciulla TA, Criswell MH, Danis RP, et al. Choroidal neovascular membrane inhibition in a laser treated rat model with intraocular sustained release triamcinolone acetonide microimplants. Br J Ophthalmol. 2003;87:1032-1037.
42. Kimura H, Sakamoto T, Hinton DR, et al. A new model of subretinal neovascularization in the rabbit. Invest Ophthalmol Vis Sci. 1995;36:2110-2119.
43. Lima e Silva R, Saishin Y, Saishin Y, et al. Suppression and regression of choroidal neovascularization by polyamine analogues. Invest Ophthalmol Vis Sci. 2005;46:3323-3330.